Your browser doesn't support javascript.
A 1-year longitudinal study on COVID-19 convalescents reveals persistence of anti-SARS-CoV-2 humoral and cellular immunity.
Li, Yang; Wang, Xi; Shen, Xu-Rui; Geng, Rong; Xie, Nan; Han, Jun-Feng; Zhang, Qing-Miao; Shi, Zheng-Li; Zhou, Peng.
  • Li Y; CAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People's Republic of China.
  • Wang X; Anyang Municipal Center for Disease Control and Prevention, Anyang, People's Republic of China.
  • Shen XR; University of Chinese Academy of Sciences, Beijing, People's Republic of China.
  • Geng R; CAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People's Republic of China.
  • Xie N; University of Chinese Academy of Sciences, Beijing, People's Republic of China.
  • Han JF; CAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People's Republic of China.
  • Zhang QM; University of Chinese Academy of Sciences, Beijing, People's Republic of China.
  • Shi ZL; CAS Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People's Republic of China.
  • Zhou P; University of Chinese Academy of Sciences, Beijing, People's Republic of China.
Emerg Microbes Infect ; 11(1): 902-913, 2022 Dec.
Article in English | MEDLINE | ID: covidwho-1730557
ABSTRACT
The immune memory of over 400 million COVID-19 convalescents is not completely understood. In this integrated study, we recorded the post-acute sequelae symptoms and tested the immune memories, including circulating antibodies, memory B cell, and memory CD4 or CD8 T cell responses of a cohort of 65 COVID-19 patients over 1-year after infection. Our data show that 48% of them still have one or more sequelae symptoms and all of them maintain at least one of the immune components. The chances of having sequelae symptoms or having better immune memory are associated with peak disease severity. We did four-time points sampling per subject to precisely understand the kinetics of durability of SARS-CoV-2 circulating antibodies. We found that the RBD IgG levels likely reach a stable plateau at around 6 months, albeit it is waning at the first 6 months after infection. At 1-year after infection, more than 90% of the convalescents generated memory CD4 or CD8 T memory responses, preferably against the SARS-CoV-2 M peptide pool. The convalescents also have polyfunctional and central memory T cells that could provide rapid and efficient response to SARS-CoV-2 re-infection. Based on this information, we assessed the immune protection against the Omicron variant and concluded that convalescents should still induce effective T cell immunity against the Omicron. By studying the circulating antibodies and memory B or T cell responses to SARS-CoV-2 in an integrated manner, our study provides insight into the understanding of protective immunity against diseases caused by secondary SARS-CoV-2 infection.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Observational study / Risk factors Topics: Long Covid / Variants Limits: Humans Language: English Journal: Emerg Microbes Infect Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Observational study / Risk factors Topics: Long Covid / Variants Limits: Humans Language: English Journal: Emerg Microbes Infect Year: 2022 Document Type: Article